Why Nyxoah SA’s (NYXH) Stock Is Up 5.91%
As of Tuesday, October 27, Nyxoah SA’s NYXH share price has surged by 5.91%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Commentary & Analysis
Why Nyxoah SA’s (NYXH) Stock Is Down 9.24%
As of Thursday, October 22, Nyxoah SA’s NYXH share price has dipped by 9.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Nyxoah SA’s (NYXH) Stock Is Down 16.10%
As of Monday, October 19, Nyxoah SA’s NYXH share price has dipped by 16.10%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Nyxoah SA’s (NYXH) Stock Is Down 15.14%
As of Monday, October 19, Nyxoah SA’s NYXH share price has dipped by 15.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nyxoah SA’s (NYXH) Stock Is Down 5.46%
As of Friday, October 16, Nyxoah SA’s NYXH share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $86.0 | $399.1 | 21% |
|
| Shares Out (Mil) | 65.1 | 40.6 | 54% |
|
| Institutional Ownership | 32.5% | 83.3% | 14% |
|
| Float (Mil) | 50.8 | 35.1 | 47% |
|
| Beta | 0.95 | 0.85 | 57% |
|
| Avg Daily Volume (000s) | 243 | 348 | 47% |
|
| Price Change (52-week) |
(83.9%) | 64.5% | 7% |
|
| Growth | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 159.6% | 11.8% | 99% |
|
| Net Income (5yr) | (47.8%) | (5.6%) | 8% |
|
| EPS (5yr) | (27.4%) | 10.6% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.365) | ($1.445) | ($0.841) | |
| Month Ago EPS | ($0.356) | ($0.685) | ($0.533) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.369) | ($0.685) | ($0.527) | |
| Year/Year Chg | (44.8%) | (47.9%) | (78.5%) | |
| Financials | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $25 | $127 | 14% |
|
| Net Income (TTM) (Mil) | ($110) | ($9) | 10% |
|
| EPS (TTM) | ($2.467) | ($0.300) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($1) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $47 | $1 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $42 | $27 | 37% |
|
| Enterprise Value (Q1) (Mil) | $119 | $390 | 22% |
|
| Valuation | NYXH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.86 | 2.61 | 22% |
|
| P/E | na | 26.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | NYXH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.2% | 59.4% | 73% |
|
| Net Margin | (443.2%) | (6.2%) | 2% |
|
| ROA | (66.6%) | (11.0%) | 9% |
|
| ROE | (121.1%) | (9.7%) | 7% |
|
| Liabilities to Assets | 50.7% | 46.5% | 43% |
|
| F-Score | 2 | 4 | 7% |
|
Nyxoah SA did not pass any screens on 11/5/2026.
